Cablivi® (caplacizumab-yhdp)

Cablivi (caplacizumab‑yhdp) is covered for adults (≥18) with acquired TTP only when initiated inpatient in combination with plasma exchange and concurrent immunosuppressive therapy, prescribed by or in consultation with a hematologist, not as monotherapy, and authorized for up to 2 months. Approval requires documentation of diagnosis/age/inpatient initiation and current immunosuppressive therapy, adherence to dosing/timing (11 mg IV bolus ≥15 minutes before PEX, 11 mg SC after PEX on day 1, then 11 mg SC daily during PEX and for 30 days after last PEX), and prior Cablivi use showing ≤2 recurrences while on therapy.

"Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy."

Sign up to see full coverage criteria, indications, and limitations.